Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course.

Lee JM, Botesteanu DA, Tomita Y, Yuno A, Lee MJ, Kohn EC, Annunziata CM, Matulonis U, MacDonald LA, Nair JR, Macneill KM, Trepel JB.

Oncol Lett. 2019 Oct;18(4):3914-3924. doi: 10.3892/ol.2019.10731. Epub 2019 Aug 7.

2.

NF-κB Signaling in Ovarian Cancer.

Harrington BS, Annunziata CM.

Cancers (Basel). 2019 Aug 15;11(8). pii: E1182. doi: 10.3390/cancers11081182. Review.

3.

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.

Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM.

J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3.

4.

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.

Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM.

Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23.

5.

Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use.

Green DS, Nunes AT, Tosh KW, David-Ocampo V, Fellowes VS, Ren J, Jin J, Frodigh SE, Pham C, Procter J, Tran C, Ekwede I, Khuu H, Stroncek DF, Highfill SL, Zoon KC, Annunziata CM.

J Transl Med. 2019 Mar 14;17(1):82. doi: 10.1186/s12967-019-1822-6.

6.

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.

JAMA Oncol. 2019 Mar 1;5(3):393-401. doi: 10.1001/jamaoncol.2018.6258.

7.

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.

Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY.

Cancer Biother Radiopharm. 2019 Apr;34(3):147-159. doi: 10.1089/cbr.2018.2628. Epub 2019 Jan 2.

8.

Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression.

Rice CM, Davies LC, Subleski JJ, Maio N, Gonzalez-Cotto M, Andrews C, Patel NL, Palmieri EM, Weiss JM, Lee JM, Annunziata CM, Rouault TA, Durum SK, McVicar DW.

Nat Commun. 2018 Nov 30;9(1):5099. doi: 10.1038/s41467-018-07505-2.

9.

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

Green DS, Nunes AT, David-Ocampo V, Ekwede IB, Houston ND, Highfill SL, Khuu H, Stroncek DF, Steinberg SM, Zoon KC, Annunziata CM.

J Transl Med. 2018 Jul 16;16(1):196. doi: 10.1186/s12967-018-1569-5.

10.

Proteasome inhibitors: structure and function.

Nunes AT, Annunziata CM.

Semin Oncol. 2017 Dec;44(6):377-380. doi: 10.1053/j.seminoncol.2018.01.004. Epub 2018 Apr 12. Review.

11.

Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.

Zhang J, Chen T, Yang X, Cheng H, Späth SS, Clavijo PE, Chen J, Silvin C, Issaeva N, Su X, Yarbrough WG, Annunziata CM, Chen Z, Van Waes C.

Cancer Res. 2018 Aug 15;78(16):4613-4626. doi: 10.1158/0008-5472.CAN-17-0642. Epub 2018 Jun 19.

12.

Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors.

Weiss JM, Davies LC, Karwan M, Ileva L, Ozaki MK, Cheng RY, Ridnour LA, Annunziata CM, Wink DA, McVicar DW.

J Clin Invest. 2018 Aug 31;128(9):3794-3805. doi: 10.1172/JCI99169. Epub 2018 Jul 30.

13.

Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target.

Brooks D, Zimmer A, Wakefield L, Lyle LT, Difilippantonio S, Tucci FC, Illiano S, Annunziata CM, Steeg PS.

Oncotarget. 2018 May 4;9(34):23462-23481. doi: 10.18632/oncotarget.25231. eCollection 2018 May 4.

14.

IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.

House CD, Grajales V, Ozaki M, Jordan E, Wubneh H, Kimble DC, James JM, Kim MK, Annunziata CM.

BMC Cancer. 2018 May 25;18(1):595. doi: 10.1186/s12885-018-4507-2.

15.

Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.

Dull AB, Wilsker D, Hollingshead M, Mazcko C, Annunziata CM, LeBlanc AK, Doroshow JH, Kinders RJ, Parchment RE.

Oncotarget. 2018 Mar 30;9(24):17104-17116. doi: 10.18632/oncotarget.24936. eCollection 2018 Mar 30.

16.

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC.

Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18.

PMID:
29361470
17.

Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.

Fantini M, David JM, Saric O, Dubeykovskiy A, Cui Y, Mavroukakis SA, Bristol A, Annunziata CM, Tsang KY, Arlen PM.

Front Immunol. 2018 Jan 4;8:1899. doi: 10.3389/fimmu.2017.01899. eCollection 2017.

18.

Clinical trials in gynecologic oncology: Past, present, and future.

Annunziata CM, Kohn EC.

Gynecol Oncol. 2018 Feb;148(2):393-402. doi: 10.1016/j.ygyno.2017.11.026. Epub 2017 Dec 6. Review.

19.

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.

Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC.

Sarcoma. 2017;2017:8685638. doi: 10.1155/2017/8685638. Epub 2017 Sep 12.

20.

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma.

Pongas GN, Annunziata CM, Staudt LM.

Oncotarget. 2017 Sep 13;8(47):81794-81802. doi: 10.18632/oncotarget.20864. eCollection 2017 Oct 10.

21.

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.

Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.

22.

NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.

House CD, Jordan E, Hernandez L, Ozaki M, James JM, Kim M, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC, Annunziata CM.

Cancer Res. 2017 Dec 15;77(24):6927-6940. doi: 10.1158/0008-5472.CAN-17-0366. Epub 2017 Oct 26.

23.

BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).

Pongas G, Kim MK, Min DJ, House CD, Jordan E, Caplen N, Chakka S, Ohiri J, Kruhlak MJ, Annunziata CM.

Oncotarget. 2017 May 3;8(31):51402-51415. doi: 10.18632/oncotarget.17572. eCollection 2017 Aug 1.

24.

Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):165-175. doi: 10.1007/s00280-017-3346-1. Epub 2017 Jun 2.

25.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.

26.

The clinical trials crisis in gynecologic oncology.

Del Carmen MG, Annunziata CM, Rice LW.

Gynecol Oncol. 2017 Jun;145(3):481-482. doi: 10.1016/j.ygyno.2017.04.003. Epub 2017 Apr 11. No abstract available.

PMID:
28410755
27.

Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas.

Sanchez-Martin D, Uldrick TS, Kwak H, Ohnuki H, Polizzotto MN, Annunziata CM, Raffeld M, Wyvill KM, Aleman K, Wang V, Marshall VA, Whitby D, Yarchoan R, Tosato G.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx016.

28.

Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome.

Wang PY, Li J, Walcott FL, Kang JG, Starost MF, Talagala SL, Zhuang J, Park JH, Huffstutler RD, Bryla CM, Mai PL, Pollak M, Annunziata CM, Savage SA, Fojo AT, Hwang PM.

J Clin Invest. 2017 Jan 3;127(1):132-136. doi: 10.1172/JCI88668. Epub 2016 Nov 21.

29.

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.

Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC.

Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.

30.

Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.

Kim MK, Caplen N, Chakka S, Hernandez L, House C, Pongas G, Jordan E, Annunziata CM.

BMC Cancer. 2016 Aug 24;16:678. doi: 10.1186/s12885-016-2675-5.

31.

SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.

Eytan DF, Snow GE, Carlson S, Derakhshan A, Saleh A, Schiltz S, Cheng H, Mohan S, Cornelius S, Coupar J, Sowers AL, Hernandez L, Mitchell JB, Annunziata CM, Chen Z, Van Waes C.

Cancer Res. 2016 Sep 15;76(18):5442-5454. doi: 10.1158/0008-5472.CAN-15-3317. Epub 2016 Jul 28.

32.

Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment.

Zeligs KP, Neuman MK, Annunziata CM.

Clin Cancer Res. 2016 Sep 1;22(17):4302-8. doi: 10.1158/1078-0432.CCR-15-1374. Epub 2016 Jul 15. Review.

33.

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, Noonan AM, Annunziata CM.

Gynecol Oncol. 2016 Aug;142(2):332-40. doi: 10.1016/j.ygyno.2016.05.028. Epub 2016 May 28.

34.

Editorial: Inhibiting PARP as a Strategic Target in Cancer.

Zorn KK, Annunziata CM.

Front Oncol. 2016 Apr 15;6:91. doi: 10.3389/fonc.2016.00091. eCollection 2016. No abstract available.

35.

Monocyte and interferon based therapy for the treatment of ovarian cancer.

Green DS, Nunes AT, Annunziata CM, Zoon KC.

Cytokine Growth Factor Rev. 2016 Jun;29:109-15. doi: 10.1016/j.cytogfr.2016.02.006. Epub 2016 Mar 15.

36.

Caspase 8 expression may determine the survival of women with ovarian cancer.

Kim M, Hernandez L, Annunziata CM.

Cell Death Dis. 2016 Jan 14;7:e2045. doi: 10.1038/cddis.2015.398. No abstract available.

37.

A dual role for Caspase8 and NF-κB interactions in regulating apoptosis and necroptosis of ovarian cancer, with correlation to patient survival.

Hernandez L, Kim MK, Noonan AM, Sagher E, Kohlhammer H, Wright G, Lyle LT, Steeg PS, Anver M, Bowtell DD; Australian Ovarian Cancer Study Group 57, Annunziata CM.

Cell Death Discov. 2015 Dec 14;1:15053. doi: 10.1038/cddiscovery.2015.53. eCollection 2015.

38.

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM.

Cancer. 2016 Feb 15;122(4):588-597. doi: 10.1002/cncr.29783. Epub 2015 Nov 13.

39.

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S.

Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7.

40.

The role of reproductive hormones in epithelial ovarian carcinogenesis.

Gharwan H, Bunch KP, Annunziata CM.

Endocr Relat Cancer. 2015 Dec;22(6):R339-63. doi: 10.1530/ERC-14-0550. Epub 2015 Sep 15. Review.

PMID:
26373571
41.

Are beta-blockers on the therapeutic horizon for ovarian cancer treatment?

Bunch KP, Annunziata CM.

Cancer. 2015 Oct 1;121(19):3380-3. doi: 10.1002/cncr.29394. Epub 2015 Aug 24. No abstract available.

42.

Voltage-gated Na+ Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling.

House CD, Wang BD, Ceniccola K, Williams R, Simaan M, Olender J, Patel V, Baptista-Hon DT, Annunziata CM, Gutkind JS, Hales TG, Lee NH.

Sci Rep. 2015 Jun 22;5:11541. doi: 10.1038/srep11541.

43.

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.

Kim MK, James J, Annunziata CM.

BMC Cancer. 2015 Mar 28;15:196. doi: 10.1186/s12885-015-1231-z.

44.

In vitro enrichment of ovarian cancer tumor-initiating cells.

House CD, Hernandez L, Annunziata CM.

J Vis Exp. 2015 Feb 18;(96). doi: 10.3791/52446.

45.
46.

The small molecule NSC676914A is cytotoxic and differentially affects NFκB signaling in ovarian cancer cells and HEK293 cells.

Sagher E, Hernandez L, Heywood C, Pauly GT, Young MR, Schneider J, Colburn NH, Annunziata CM.

Cancer Cell Int. 2014 Aug 12;14:75. doi: 10.1186/s12935-014-0075-y. eCollection 2014.

47.

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.

J Natl Cancer Inst. 2014 May 19;106(6):dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.

48.

Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.

Szabova L, Bupp S, Kamal M, Householder DB, Hernandez L, Schlomer JJ, Baran ML, Yi M, Stephens RM, Annunziata CM, Martin PL, Van Dyke TA, Weaver Ohler Z, Difilippantonio S.

PLoS One. 2014 Apr 18;9(4):e95649. doi: 10.1371/journal.pone.0095649. eCollection 2014.

49.

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.

Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC.

Mol Clin Oncol. 2013 May;1(3):565-569. Epub 2013 Mar 20.

50.

Recent technological advances in using mouse models to study ovarian cancer.

House CD, Hernandez L, Annunziata CM.

Front Oncol. 2014 Feb 13;4:26. doi: 10.3389/fonc.2014.00026. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center